BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Ipsen still in buying mode after $247M Epizyme takeover; bigger deals ahead?
After its $247 million acquisition of Epizyme Inc., Ipsen SA will continue to shop for M&A prospects, said Ipsen CEO David Loew, noting that “the [company’s] firepower has...

More in BioWorld

BioWorld MedTech

Patient Square hears the call of Eargo, invests $125M
Sounds like Eargo Inc. received good news as Patient Square Capital signed a definitive agreement to purchase $100 million in senior secured convertible notes plus an...

More in BioWorld MedTech

BioWorld Science

Molecular signature predicts cancer risk in patients with NAFLD
Research led by the University of Texas Southwestern Medical Center reveals a protein signature that can reliably predict whether patients with nonalcoholic fatty liver disease (NAFLD) are likely to develop hepatocellular carcinoma, the most common form of liver cancer.

More in BioWorld Science

BioWorld Asia

WTO’s COVID-19 IP waiver playing to rotten tomatoes
While the World Trade Organization (WTO) is taking a victory lap for getting a five-year intellectual property (IP) waiver across the finish line for COVID-19 vaccines, the...

More in BioWorld Asia

BioWorld Insider Podcast

As multidisciplinary care extends survival and improves the quality of life for people with amyotrophic lateral sclerosis (ALS), can a host of new ALS drugs vying to slow its progression make a difference? Join the BioWorld Insider podcast as we discuss what the future of medicine may hold for ALS patients.